FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908049261> ?p ?o ?g. }

• W2908049261 endingPage "512" @default.
• W2908049261 startingPage "502" @default.
• W2908049261 abstract "BACKGROUND: To evaluate the efficacy and toxicities of regorafenib plus irinotecan, dose-escalated on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping, in previously heavily treated metastatic colorectal cancer (mCRC) and the prognostic values of EGFR expression, KRAS mutations, and tumor sidedness. METHODS: Forty-one patients with mCRC with disease progression after treatment with fluoropyrimidines, oxaliplatin, irinotecan, anti-VEGF, and anti-EGFR MoAbs were subjected to UGT1A1 genotyping and received regorafenib combined with FOLFIRI with dose-escalated irinotecan. RESULTS: The median follow-up period was 10.0 months (1.3-23.5 months). The overall disease control rate was 58.5%, whereas the median progression-free survival (PFS) and overall survival (OS) were 6.0 months and 12.0 months, respectively. KRAS mutations were significantly associated with positive EGFR expression (P = .026). KRAS mutations significantly correlated with a shorter OS than KRAS wild-type (6.0 vs. 14.4 months, P = .014) but had no significant association with PFS. Positive EGFR expression had an inverse correlation with PFS (2.5 vs. 14.0 months, P = .039) and OS (9.6 vs. 19.7 months, P = .044). Moreover, left-sided tumors associated with superior PFS (2.0 vs. 7.0 months, P < .0001) and OS (4.0 vs. 13.0 months, P < .0001), and tumor sidedness was an independent prognostic factor by the multivariate analysis. CONCLUSION: Regorafenib and FOLFIRI concomitant therapy with dose-escalated irinotecan seemed to be potentially practicable with satisfactory oncological results. KRAS mutations and EGFR expression might be predictors of poor oncological outcomes; however, left-sided mCRCs would be more beneficial for concomitant regorafenib and FOLFIRI therapy." @default.
• W2908049261 created "2019-01-11" @default.
• W2908049261 creator A5008262587 @default.
• W2908049261 creator A5009015283 @default.
• W2908049261 creator A5017581674 @default.
• W2908049261 creator A5020320585 @default.
• W2908049261 creator A5022368844 @default.
• W2908049261 creator A5047472928 @default.
• W2908049261 creator A5053604127 @default.
• W2908049261 creator A5074484179 @default.
• W2908049261 date "2019-03-01" @default.
• W2908049261 modified "2023-10-15" @default.
• W2908049261 title "Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting" @default.
• W2908049261 cites W1504814099 @default.
• W2908049261 cites W1777256341 @default.
• W2908049261 cites W1934094702 @default.
• W2908049261 cites W1968209756 @default.
• W2908049261 cites W1972082105 @default.
• W2908049261 cites W1974365085 @default.
• W2908049261 cites W1976103150 @default.
• W2908049261 cites W1983143162 @default.
• W2908049261 cites W1999250974 @default.
• W2908049261 cites W2009190848 @default.
• W2908049261 cites W2011492006 @default.
• W2908049261 cites W2018804685 @default.
• W2908049261 cites W2019607817 @default.
• W2908049261 cites W2022508169 @default.
• W2908049261 cites W2026037118 @default.
• W2908049261 cites W2029130050 @default.
• W2908049261 cites W2034338421 @default.
• W2908049261 cites W2051444430 @default.
• W2908049261 cites W2054301472 @default.
• W2908049261 cites W2058849572 @default.
• W2908049261 cites W2066316757 @default.
• W2908049261 cites W2076034513 @default.
• W2908049261 cites W2077428590 @default.
• W2908049261 cites W2082379978 @default.
• W2908049261 cites W2084653234 @default.
• W2908049261 cites W2085633477 @default.
• W2908049261 cites W2086127297 @default.
• W2908049261 cites W2095201384 @default.
• W2908049261 cites W2098223440 @default.
• W2908049261 cites W2108455517 @default.
• W2908049261 cites W2111851685 @default.
• W2908049261 cites W2120490763 @default.
• W2908049261 cites W2122517534 @default.
• W2908049261 cites W2127640925 @default.
• W2908049261 cites W2131413118 @default.
• W2908049261 cites W2132545630 @default.
• W2908049261 cites W2134519717 @default.
• W2908049261 cites W2140143664 @default.
• W2908049261 cites W2147834058 @default.
• W2908049261 cites W2164837623 @default.
• W2908049261 cites W2168083201 @default.
• W2908049261 cites W2192922095 @default.
• W2908049261 cites W2318194385 @default.
• W2908049261 cites W2336217205 @default.
• W2908049261 cites W2443622314 @default.
• W2908049261 cites W2461639220 @default.
• W2908049261 cites W2465450966 @default.
• W2908049261 cites W2467206133 @default.
• W2908049261 cites W2520338075 @default.
• W2908049261 cites W2535069604 @default.
• W2908049261 cites W2552186799 @default.
• W2908049261 cites W2564004547 @default.
• W2908049261 cites W2583753128 @default.
• W2908049261 cites W2618095691 @default.
• W2908049261 cites W2738363017 @default.
• W2908049261 cites W2808944387 @default.
• W2908049261 cites W2889916101 @default.
• W2908049261 doi "https://doi.org/10.1016/j.tranon.2018.12.003" @default.
• W2908049261 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6307535" @default.
• W2908049261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30594039" @default.
• W2908049261 hasPublicationYear "2019" @default.
• W2908049261 type Work @default.
• W2908049261 sameAs 2908049261 @default.
• W2908049261 citedByCount "14" @default.
• W2908049261 countsByYear W29080492612019 @default.
• W2908049261 countsByYear W29080492612020 @default.
• W2908049261 countsByYear W29080492612022 @default.
• W2908049261 countsByYear W29080492612023 @default.
• W2908049261 crossrefType "journal-article" @default.
• W2908049261 hasAuthorship W2908049261A5008262587 @default.
• W2908049261 hasAuthorship W2908049261A5009015283 @default.
• W2908049261 hasAuthorship W2908049261A5017581674 @default.
• W2908049261 hasAuthorship W2908049261A5020320585 @default.
• W2908049261 hasAuthorship W2908049261A5022368844 @default.
• W2908049261 hasAuthorship W2908049261A5047472928 @default.
• W2908049261 hasAuthorship W2908049261A5053604127 @default.
• W2908049261 hasAuthorship W2908049261A5074484179 @default.
• W2908049261 hasBestOaLocation W29080492611 @default.
• W2908049261 hasConcept C104317684 @default.
• W2908049261 hasConcept C121608353 @default.
• W2908049261 hasConcept C126322002 @default.
• W2908049261 hasConcept C135763542 @default.
• W2908049261 hasConcept C143998085 @default.
• W2908049261 hasConcept C185592680 @default.
• W2908049261 hasConcept C2776248978 @default.

• next